Dr. John Scarlett
whether Then to with once how Janssen’s of trials. I’m we’ve IMerge we’ve decision updates I’ll decision. each IMbark our potentially imetelstat. thoughts to been respond influencing finish been the first of on I’ll Janssen’s preparing elect development continue of and going Thanks, to provide scenario of they Olivia. to provide informed the components
or syndrome myelodysplastic and IMerge on comments few a First, MDS.
XX not trials HMAs lenalidomide patient EHA XX response XX number patient treatment weeks. with patients of week to the prior before IMerge in with time of IMerge entering reflected TI treatment these medium intermediate trial patients in restrict MDS did prior or the who cohort presented enrolled lenalidomide. Stockholm. also with stimulating del(Xq) comparison follow-up XX in for an an ESA. of either from hypomethylating dependent did in a treatments or of risk XXrd American Part lower data type the which one the received the XX non-del(Xq) agents patients a treatment rate for and Among As agent originally IMerge to transfusion as the not erythropoiesis chromosomal who reported imetelstat for or or risk in original inclusion subset and was Part updated Annual who X total abnormality. patients refractory that of you, variety XX% original a This presentation The two-part at relapsed compared or the a clinical a had of are eight-week follow-up independence of longer of is HMAs of after have or MDS, received patients of a rate this with low of after of the Meeting was criteria or patients showed were Annual transfusion time. X is eight Association of December open-label that the the ASH On of or of X parts achieved not has XXXX X blood Congress least yet at Hematology Phase endpoint place EHA, X double for study. period is The weeks the European X percentage IMerge the begun. study a year, trial. Part rate outcome the MDS treatment trial at both prior the treatments. XXth original patients, of XX%. cell eight-week XX exclusion XX% an at was IMerge Society June had controlled Hematology meaningful to These of a Phase and with IMerge reported the cohort TI not prior or updated red blind clinically Part after is or Because primary TI other evaluating data of presentation
treatment with For positioned patients imetelstat HMA could most currently lower either believe more or represent suggested generally TI XX%. treatment the favorable this efficacy MDS outcome We imetelstat to a ESA HMAs. lenalidomide. with impressive could for from or ESAs to risk XX was patient a since and subset, with These treatment an treatment rate prior with with non-del(Xq) proceed of positioning failure lenalidomide commercial eight-week results an encouraging after the be as potential proceeding
approved in HMAs patients the and additional the In where imetelstat of European confirm quarter physicians and treatment Janssen X lower enroll for lenalidomide alternative target naïve to benefit risk for and the MDS. needed to risk could in In refined XXXX, fourth XX much expanded IMerge population. Part imetelstat especially the addition, Union not offer this increase HMA are profile and non-del(Xq) order lenalidomide of experience an patients, in
using two Next, date. inhibitor. specified by IMbark believe timing patients includes a data protocol continuation from the relapsed analysis, X is MF, the a In survival, who the Janssen of and of timing The clinical we are quarter have myelofibrosis of Phase trials. initiated which XXth to third the this we in overall decision analysis IMbark intermediate year, or MF, or the to consider high-risk assessment primary by will clinical trial as Janssen as of In prior of after the continue decision-making with an April IMbark or treatment and the end of our reminder, primary a process, with JAK refractory quarter. both driven expect the their that totality of of decision completion is cutoff their second Janssen’s
a other treatment for we few by other of control Since options. who their failed imetelstat inhibitor because to overall believe not an arm, development survival or expect overall there they looking warrant overall For to with in treatment. Janssen will relapsed/refractory have on assessment, survival IMbark, can improvement IMbark projected at from does refractory is similar MF to been overall patient in whether focus further populations, the make median survival have JAK be patients survival, IMbark own have trials eligible Janssen contextualized only assessment adequate of MF.
we expect the the the efficacy portion of outcomes two, patient cohort assessing whether analysis enabling safety IMerge. refined patients which focus of subset, IMerge, from move Phase on in forward target population the thus For additional the patient are with consistent part X XX is to Janssen’s will them to XX and
that potential be terms be and they other for for Janssen’s strategy, agreement with likely highly non-imetelstat rep will and but related and corporate future collaboration them whether beneficial MDS portfolio of preliminary from factors data Such receive IMbark to pursued programs Janssen Janssen, include therapeutic pursued to development the time remain and except commercialization, The could the could factors by their to primary the are will of data market package assessment areas the indications with costs expect of other costs relevant and further the refined of any associated We data of circumstances. number the the not of as decision, number, and patients imetelstat of the which Beyond to which in original of expect MF and development comments population in Janssen we target consider. there imetelstat. from contents believe expect studies, will from not to the do including analysis prior cohort the all the decision-making, Janssen’s IMerge, from this certain Janssen’s XX-patient In with connection being on their results package enrolled. information include we of provide the recently or the additional subset timing XX focus. under
that For a conclusion Janssen do and prior example, imetelstat, both expect Geron, Steering the the members not a if development of of such support Janssen further determines Committee, Joint would we disclose comprised of then data even decision. to to
conference medical Janssen we us expect Janssen IMbark of both customary from presentations, presentation be and to their at from We such data submit medical embargo maintain not Therefore the either do for conferences. to IMerge, decision. notifies data publicly for trial future to anticipate before potential presented
resulting address the Janssen’s discus from been let’s preparing we’ve Now, plans that either scenario decision. upcoming
as order way decision. payment future U.S. The it XX:XX, would also future for of be Geron development the and the ratio in Janssen has would promotional imetelstat place structure Under to milestones, activities, of to the -- be in commercialization to opt-out the deciding in would whether The million decide agreement. terms affirmative us an describe function The and information million respectively and milestones. of provide to they imetelstat, our and timing and on eligible package for the choices beginning well our license they and percentage decision. for costs. to Janssen collaboration royalty of according Janssen. related receive we mid-teens low plans million assuming the current to $XXX their in remain milestone agreement the tier and joint will of of for collaboration First, opt-in that We in provide would $XXX for the in in opt-in same to cost-sharing I’ll imetelstat. to continue us estimates continue, future potential for the governance XXs since under affirmative scenario, sales would $XX promotional Geron Should continuation a as collaboration. regulatory sales up or development development with a includes decide cost be to continuation assist
would of for We addition, costs, milestone promotion an rights. plans and in also to sales for to of imetelstat. tier potential imetelstat, milestones. in if in million we milestone installment opt-out percentage double-digit on have $XX continuation $XX and independent million eligible The XXX% opportunity U.S. be agreed to the scenario, the by of Janssen’s receive development sales the be of periodic future receive for IDPs payment program Under to and undertake we retention not We addition future the would In driven development Joint payment, milestones $XXX or solely be million scenario, conduct this would Committee. would future would development only updates. IDPs. regulatory and by we the able additional be Governance any mid-teens $XXX governance imetelstat would million up royalty pays Janssen would Janssen to full In
As attention a our diversify on BD would result, we business. to focus our
clinical as financial should of whether of or Geron. proposed development impact a opt-out, analysis would well on strategic decision plan, we Our Janssen’s opt-in as considering involve
has contrast, expect we to warrant to program imetelstat of should MF, they our when X Janssen the de-risking in both we hand discontinue is and evaluated collaboration de-risked back much development drug Geron, and plans assuming imetelstat Phase decide clinical imetelstat imetelstat and have development, to From data as of Now, initiate to to move which for the continued imetelstat done. the been rights forward. Janssen, MDS by believe the in is the with development the perspective,
to each and we this of myeloid management for imetelstat our from the profile of malignancy good a IMerge and indication, understanding in very hold understanding these toxicities. IMbark safety us to expect and and the two the hematologic initial appropriate addition give In indications, hematologic the rules dose data in dose efficacy of enhancing modification
affects with what target is pharmacokinetic of it variety drug wide including a genomic endpoints, each and the We performs respect engagement indication, analysis. secondary to and exploratory profile to and in also understand how the expect how
action after IMerge Phase of a and hand sponsorships and path development, X of the of portion warrant insights In initiate X already protocol familiar been that in the vitro Geron. number back operational large from We potential of half vivo believe the gain MDS expect we are the a scenario, including of of because regulatory a addition, of of our sites drug data Phase priority Part imetelstat with back into to to variety the to clinical and continued X already established, we XXXX, R&D development the clinical Under assuming the lower and that been would clinical be first a presents IMerge in mechanism designed, endpoints have of Part the straightforward risk to transferred in has X. been from approval, studies. the expect further portion have
the we information leaders in addition, with these to one opinion of well better who Also medical In as We potential MDS as design relapsed primary how are could authorities. be important results patients and research warrant need under internationally by given recognized the current unmet believe and scenario further on engage will and the future risk trials intend imetelstat the clinical scope of physicians, development, discuss a the to from firm potential analysis IMbark MF, we in intermediate treatments. MF inhibitor. understand and discussions imetelstat high-risk key the hand or provide back assuming lower future to imetelstat, two used for any of refractory and JAK feedback regulatory in data
scenario of to and as development functional would developed data research responsibility areas, oversight plan, plan global provide contract or all local employees Our [ph], organization affairs, CRO CRO, to to management, is that for The of the select team, a in the capabilities clinical objectives pharmacovigilance, operational quality. the internal teams by in technical regulatory the CNMC have been planning identify assume key Geron’s a hand and operational well consultants. development comprised order and potentially cross as and back being including, biostatistics operations, for establish
support expect unless continue. than scenario the would contract decides take we CRO, we to development of either we back Geron. as needed position ahead prepared scenario. the would, Janssen that in of to we’re not on us the long-term the decision. operational believe our imetelstat of all Janssen In closing, a into not to course, Janssen’s program of to been as Despite the can to advancement responsibilities of with enter the the focused transition Of potential if longer preparations, We’ve it continued, because we for in time be this imetelstat priorities imetelstat
result, our our going a effectively forward. in to manage we’re business ability confident As
the like and to answer we’d operator. So, your I’ll to back questions call turn our
